Topic guide
Safety & Ethics
Screening, contraindications, professional boundaries, informed consent and the systems needed to protect participants and patients.
Start with context
Safety is more than the acute pharmacology of a substance. It includes selection, preparation, monitoring, psychological vulnerability, professional conduct, complaints, data integrity and long-term follow-up.
Questions this topic raises
- Who is screened out—and why?
- What happens if distress or a medical problem occurs?
- Are professional roles and touch boundaries explicit?
- Can participants report concerns independently?
- Are adverse events and limitations reported transparently?
Read the evidence guides
Screening, Contraindications and Risk in Psychedelic Research
What clinical trials screen and monitor—and why selected study populations cannot be generalised.
Therapists, Boundaries and Safeguarding in Psychedelic Research
Why altered states heighten safeguarding duties and what responsible oversight should include.
How to Spot Misleading Psychedelic Clinic and Retreat Claims
Test treatment promises, credentials, regulation, testimonials and safety claims before money or trust changes hands.
What Does “Psychedelic-Assisted Therapy” Really Mean?
A guide to preparation, monitored sessions, psychological support and integration.
MDMA-Assisted Therapy for PTSD: Evidence, Limits and Approval Status
What phase 3 trials reported, why the FDA did not approve the application and what remains unresolved.
Keep the boundary clear
These guides are educational. They do not provide medical advice, personalised risk assessment, legal advice or instructions for using a controlled substance.
